Waging Peace.
Fighting Disease.
Building Hope.

River Blindness Elimination Program

Our Goal

The Carter Center works with national ministries of health in Latin America and Africa to eliminate river blindness, one of the leading causes of preventable blindness worldwide.


What is River Blindness?

River blindness, also known as onchocerciasis, is a parasitic infection that can cause intense itching, skin discoloration, rashes, and eye disease that often leads to permanent blindness. It is spread by the bites of infected black flies that breed in rapidly flowing rivers.


How Widespread is the Problem?

Onchocerciasis has affected countries in Africa and Latin America, as well as Yemen. The disease can cause intense itching, eye damage, and irreversible blindness, reducing an individual's ability to work and learn.

The Carter Center currently works to eliminate river blindness together with the following countries: Brazil, Ethiopia, Guatemala, Nigeria, Sudan, Uganda, and Venezuela. The Carter Center's Onchocerciasis Elimination Program for the Americas also partners with the Ministries of Health in Colombia, Ecuador, and Mexico. Those three nations received official verification of onchocerciasis elimination in 2013, 2014, and 2015, respectively.


Our Strategy

The Carter Center currently assists ministries of health in eight nations to eliminate river blindness through health education and distribution of the medicine Mectizan®, donated by Merck.

Mectizan kills the parasite larvae in the human body, preventing blindness and transmission of river blindness to others. The Carter Center mobilizes communities to distribute Mectizan and provide health education through local agencies and networks.

Based on findings of the 2002 Conference on the Eradicability of Onchocerciasis hosted at The Carter Center, river blindness is not currently globally eradicable. However, The Carter Center is working to eliminate it in select regions.

In Latin America, where less than 1 percent of river blindness cases exist, The Carter Center works through its Onchocerciasis Elimination Program for the Americas (OEPA) to eliminate the disease from the region. Today, efforts focus on Brazil and Venezuela, where transmission of the last cases in the Americas still occurs in an isolated area on the border of the two countries.

In Africa, where more than 99 percent of the global cases exist, successes at nearly eliminating river blindness in Uganda and Sudan have spurred river blindness elimination projects in Ethiopia and Nigeria.


Results and Impact

To date, the Center with its partners has:

  • Distributed more than 200 million treatments of Mectizan® in Africa and Latin America.

  • Interrupted transmission of river blindness in 11 foci of the 13 endemic areas in the Americas through health education and Mectizan distribution. In 2013, Colombia became the first country in the Americas to eliminate river blindness and the first country in the world to be granted verification of elimination of river blindness by the World Health Organization. Ecuador and Mexico followed in Colombia's steps, receiving official verification of elimination in 2014 and 2015, respectively.

  • Demonstrated that river blindness elimination is possible in regions of Africa, where it was long thought to be too prevalent to tackle.

  • Stopped river blindness transmission from 15 of the original 17 foci in Uganda, enabling 2.7 million Ugandans to be free from the scourge.

  • Stopped river blindness transmission in Abu Hamad, Sudan, the most isolated focus area in the world, with more than 100,000 no longer at risk of the disease.


The Carter Center is committed to creating a world where every child, woman, and man has the opportunity to live in peace and enjoy good health.

Learn more about how your donations help >


Sign Up for Email Updates

Thanks for Signing Up!

Please leave this field empty

Thanks for Staying Updated!

Now, we invite you to Get Involved

The Carter Center works to eliminate river blindness, not just control it, in all the areas where we are fighting this neglected disease in Africa and Latin America. Read more >